Last $10.73 USD
Change Today -0.17 / -1.56%
Volume 630.8K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

pernix therapeutics holdings (PTX) Snapshot

Open
$10.84
Previous Close
$10.90
Day High
$11.00
Day Low
$10.72
52 Week High
11/12/14 - $11.68
52 Week Low
03/14/14 - $3.44
Market Cap
410.9M
Average Volume 10 Days
635.9K
EPS TTM
$-0.73
Shares Outstanding
38.3M
EX-Date
09/8/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PERNIX THERAPEUTICS HOLDINGS (PTX)

Related News

No related news articles were found.

pernix therapeutics holdings (PTX) Related Businessweek News

No Related Businessweek News Found

pernix therapeutics holdings (PTX) Details

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product include CEDAX, a oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; REZIRA, ZUTRIPRO, and VITUZ, which are oral solutions for the relief of cough and nasal congestion; and OMECLAMOX-PAK to treat patients with H.pylori infection and duodenal ulcer disease. Its products also comprise SILENOR, a prescription medicine used to treat insomnia characterized by difficulty with sleep maintenance; KHEDEZLA, a prescription medicine for the treatment of major depressive disorder; and NATROBA, a prescription medicine used to treat head lice. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women’s health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is based in Morristown, New Jersey.

pernix therapeutics holdings (PTX) Top Compensated Officers

Principal Accounting Officer and Corporate Co...
Total Annual Compensation: $208.3K
Compensation as of Fiscal Year 2013.

pernix therapeutics holdings (PTX) Key Developments

Pernix Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reiterates Earnings Guidance for the Year 2015

Pernix Therapeutics Holdings, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net revenue of $53.834 million against $23.926 million a year ago. Loss from operations was $2.620 million against $32.782 million a year ago. Loss before income taxes was $12.584 million against $19.314 million a year ago. Net loss was $7.819 million or $0.20 per basic and diluted share against $6.224 million or $0.17 per basic and diluted share a year ago. EBITDA was $16.060 million against LBITDA of $16.500 million a year ago. Adjusted EBITDA was $22.861 million or $0.39 per diluted share against $1.127 million or $0.03 per basic and diluted share a year ago. Adjusted net income was $14.549 million or $0.25 per diluted share against $6.296 million or $0.17 per basic and diluted share a year ago. For the year, the company reported net revenue of $121.747 million against $84.872 million a year ago. Loss from operations was $30.214 million against $54.661 million a year ago. Loss before income taxes was $49.011 million against $46.392 million a year ago. Net loss was $35.286 million or $0.93 per basic and diluted share against $25.635 million or $0.70 per basic and diluted share a year ago. EBITDA was $2.785 million against LBITDA of $33.666 million a year ago. Adjusted EBITDA was $23.846 million or $0.44 per diluted share against adjusted LBITDA of $5.699 million or $0.16 per basic and diluted share a year ago. Adjusted net income was $9.858 million or $0.18 per basic and diluted share against adjusted net loss of $2.157 million or $0.06 per basic and diluted share a year ago. For the year 2015, the company confirms its prior guidance of $230 million of net revenues and $95 million of adjusted EBITDA.

Pernix Therapeutics Holdings, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015

Pernix Therapeutics Holdings, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 . Venue: The New York Palace Hotel, New York, New York, United States.

Pernix Therapeutics Holdings, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 11:10 AM

Pernix Therapeutics Holdings, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 11:10 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Sanjay Patel, Chief Financial Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTX:US $10.73 USD -0.17

PTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Interpharm Holdings Inc $0.0010 USD 0.00
Momenta Pharmaceuticals Inc $13.65 USD -0.29
OraSure Technologies Inc $7.16 USD -0.29
SciClone Pharmaceuticals Inc $7.71 USD 0.00
Sucampo Pharmaceuticals Inc $15.38 USD -0.62
View Industry Companies
 

Industry Analysis

PTX

Industry Average

Valuation PTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERNIX THERAPEUTICS HOLDINGS, please visit www.pernixtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.